As of 2025-03-17, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -5.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 174.59 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -33.92 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.3x - 8.4x | 6.5x |
| Forward P/E multiples | 7.7x - 9.9x | 9.6x |
| Fair Price | (1.97) - (0.05) | (1.45) |
| Upside | -205.1% - -102.9% | -177.5% |
| Date | EV/EBITDA |
| 2025-03-14 | -5.15 |
| 2025-03-13 | -5.16 |
| 2025-03-12 | -5.22 |
| 2025-03-11 | -5.20 |
| 2025-03-10 | -5.32 |
| 2025-03-07 | -5.54 |
| 2025-03-06 | -5.41 |
| 2025-03-05 | -5.51 |
| 2025-03-04 | -5.42 |
| 2025-03-03 | -5.64 |
| 2025-02-28 | -5.77 |
| 2025-02-27 | -5.97 |
| 2025-02-26 | -6.03 |
| 2025-02-25 | -5.86 |
| 2025-02-24 | -6.13 |
| 2025-02-21 | -5.96 |
| 2025-02-20 | -5.71 |
| 2025-02-19 | -5.85 |
| 2025-02-18 | -5.77 |
| 2025-02-17 | -5.69 |
| 2025-02-14 | -5.28 |
| 2025-02-13 | -5.26 |
| 2025-02-12 | -5.22 |
| 2025-02-11 | -5.28 |
| 2025-02-10 | -5.32 |
| 2025-02-07 | -5.36 |
| 2025-02-06 | -5.49 |
| 2025-02-05 | -5.30 |
| 2025-02-04 | -5.34 |
| 2025-02-03 | -4.89 |
| 2025-01-31 | -4.97 |
| 2025-01-30 | -4.84 |
| 2025-01-29 | -4.76 |
| 2025-01-28 | -4.81 |
| 2025-01-27 | -4.85 |
| 2025-01-24 | -4.74 |
| 2025-01-23 | -4.75 |
| 2025-01-22 | -4.83 |
| 2025-01-21 | -4.85 |
| 2025-01-20 | -4.79 |
| 2025-01-17 | -4.80 |
| 2025-01-16 | -4.82 |
| 2025-01-15 | -4.89 |
| 2025-01-14 | -5.02 |
| 2025-01-13 | -5.07 |
| 2025-01-10 | -4.99 |
| 2025-01-09 | -4.89 |
| 2025-01-08 | -5.02 |
| 2025-01-07 | -5.09 |
| 2025-01-06 | -5.14 |